McKesson Co. (NYSE:MCK) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of McKesson Co. (NYSE:MCK - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fifteen ratings firms that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $686.69.

A number of brokerages have weighed in on MCK. Wall Street Zen lowered McKesson from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 21st. Mizuho raised their price objective on McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a report on Thursday, April 3rd. Wells Fargo & Company raised their price objective on McKesson from $641.00 to $691.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Evercore ISI raised their price objective on McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Finally, Bank of America raised their price objective on McKesson from $755.00 to $800.00 and gave the company a "buy" rating in a report on Friday, May 9th.

Insider Activity at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 543 shares of McKesson stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $726.51, for a total value of $394,494.93. Following the completion of the transaction, the chief accounting officer now directly owns 1,972 shares of the company's stock, valued at $1,432,677.72. The trade was a 21.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Britt J. Vitalone sold 6,336 shares of McKesson stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $717.30, for a total value of $4,544,812.80. Following the completion of the transaction, the chief financial officer now directly owns 14,760 shares of the company's stock, valued at approximately $10,587,348. This represents a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,127 shares of company stock worth $5,834,498. Company insiders own 0.11% of the company's stock.

Institutional Trading of McKesson

A number of large investors have recently made changes to their positions in the company. CVA Family Office LLC increased its stake in shares of McKesson by 6.0% during the first quarter. CVA Family Office LLC now owns 265 shares of the company's stock worth $178,000 after buying an additional 15 shares during the period. Palisade Asset Management LLC increased its stake in shares of McKesson by 2.1% during the first quarter. Palisade Asset Management LLC now owns 715 shares of the company's stock worth $481,000 after buying an additional 15 shares during the period. SteelPeak Wealth LLC increased its stake in shares of McKesson by 0.5% during the first quarter. SteelPeak Wealth LLC now owns 2,771 shares of the company's stock worth $1,867,000 after buying an additional 15 shares during the period. Parallel Advisors LLC increased its stake in shares of McKesson by 0.6% during the first quarter. Parallel Advisors LLC now owns 2,501 shares of the company's stock worth $1,683,000 after buying an additional 16 shares during the period. Finally, Frank Rimerman Advisors LLC increased its stake in shares of McKesson by 2.2% during the fourth quarter. Frank Rimerman Advisors LLC now owns 807 shares of the company's stock worth $460,000 after buying an additional 17 shares during the period. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Stock Performance

McKesson stock traded down $8.77 during trading on Monday, reaching $711.61. The company had a trading volume of 638,870 shares, compared to its average volume of 917,912. The firm's 50-day simple moving average is $691.98 and its 200 day simple moving average is $635.78. McKesson has a 1-year low of $464.42 and a 1-year high of $731.00. The firm has a market capitalization of $89.03 billion, a PE ratio of 32.58, a price-to-earnings-growth ratio of 1.29 and a beta of 0.53.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $10.12 earnings per share for the quarter, beating analysts' consensus estimates of $9.83 by $0.29. The company had revenue of $90.82 billion for the quarter, compared to analyst estimates of $94 billion. McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter last year, the firm posted $6.18 EPS. Analysts anticipate that McKesson will post 32.77 EPS for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Monday, June 2nd will be issued a $0.71 dividend. The ex-dividend date of this dividend is Monday, June 2nd. This represents a $2.84 annualized dividend and a yield of 0.40%. McKesson's dividend payout ratio (DPR) is currently 10.99%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.